Core Viewpoint - Qingdao Baiyang Pharmaceutical Co., Ltd. has signed a market promotion cooperation agreement with Beijing Huahao Zhongtian Biopharmaceutical Co., Ltd. for the exclusive promotion rights of the innovative drug Yutidelong in mainland China [1][2] Group 1: Agreement Details - Baiyang Pharmaceutical will pay an upfront non-refundable fee of 50 million RMB to Huahao Zhongtian and will also pay milestone payments based on research and sales progress [1] - Huahao Zhongtian will pay Baiyang Pharmaceutical a promotion service fee based on annual terminal sales [1] Group 2: Product Information - Yutidelong is the only domestically developed microtubule inhibitor innovative drug and the first approved new drug for treating recurrent or metastatic advanced breast cancer since 2010 [1][2] - The drug has shown benefits in progression-free survival (PFS) and overall survival (OS) for advanced breast cancer patients, with a safety profile that is more advantageous [2] Group 3: Market Potential - With the aging population and increasing cancer patient demographics, Yutidelong has significant market potential, especially as it fills a gap in the National Medical Insurance Drug List for domestic innovative microtubule inhibitors [2] - The collaboration is expected to enhance Baiyang Pharmaceutical's product matrix in the oncology innovative drug sector [3]
百洋医药牵手华昊中天，加速推进全球首个微管抑制剂1类创新药商业化进程